Accelerating Early ADC Clinical Development with a Differentiated Strategy
- Accessing unique patient populations and enriching enrollment with those more likely to relapse with a comprehensive biomarker approach that integrates CGP, MRD, multi-omics, and RWD
- Detecting molecular response within weeks of therapy initiation and identifying which patients are benefiting
- Enhancing clinical development and trial designs by using ctDNA for response monitoring to allow for earlier efficacy readouts and as an early surrogate endpoint to support regulatory conversations